Table 3.
Precision, Recall, and F-measure of the automatically generated answers for the base questions.
| ID | Question | P | R | F | ID | Question | P | R | F |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Patient’s vital status | 1.000 | 1.000 | 1.000 | 23 | Date of first recurrence or progression | 1.000 | 1.000 | 1.000 |
| 2 | Hemoglobin (Hgb) | 1.000 | 1.000 | 1.000 | 24 | Primary site(s)2 | 1.000 | 1.000 | 1.000 |
| 3 | Absolute neutrophil count | 1.000 | 1.000 | 1.000 | 25 | Tumor size | 1.000 | 1.000 | 1.000 |
| 4 | Absolute neutrophil count LNL | 1.000 | 1.000 | 1.000 | 26 | Bowel perforation2 | 1.000 | 1.000 | 1.000 |
| 5 | Creatinine | 1.000 | 1.000 | 1.000 | 27 | Histologic type | 1.000 | 1.000 | 1.000 |
| 6 | Creatinine UNL | 1.000 | 1.000 | 1.000 | 28 | Histology | 1.000 | 1.000 | 1.000 |
| 7 | Platelet count | 1.000 | 1.000 | 1.000 | 29 | Comments2 | 1.000 | 0.955 | 0.977 |
| 8 | Total bilirubin | 1.000 | 1.000 | 1.000 | 30 | Adherence | 0.909 | 0.769 | 0.833 |
| 9 | Total bilirubin UNL | 1.000 | 1.000 | 1.000 | 31 | Number of deposits | 1.000 | 0.997 | 0.998 |
| 10 | Negative serum pregnancy test | 1.000 | 1.000 | 1.000 | 32 | Disease extent2 | 1.000 | 0.994 | 0.997 |
| 11 | Negative serum pregnancy test date | 1.000 | 1.000 | 1.000 | 33 | Regional lymph node involvement | 1.000 | 0.995 | 0.997 |
| 12 | Assigned treatment (medication) | 1.000 | 1.000 | 1.000 | 34 | Number of lymph nodes examined2 | 1.000 | 0.997 | 0.999 |
| 13 | Associated diseases | 1.000 | 0.952 | 0.976 | 35 | Positive lymph nodes2 | 1.000 | 0.989 | 0.994 |
| 14 | Clinical assessment date | 1.000 | 1.000 | 1.000 | 36 | Distance to closest longitudinal margin | 1.000 | 0.697 | 0.822 |
| 15 | Colonoscopy Date | 0.997 | 1.000 | 0.998 | 37 | Bowel obstruction2 | 1.000 | 1.000 | 1.000 |
| 16 | Extent of resection | 0.890 | 0.973 | 0.930 | 38 | Blocks | 1.000 | 1.000 | 1.000 |
| 17 | Type of procedure2 | 0.997 | 0.985 | 0.991 | 39 | Stools | - | - | - |
| 18 | Surgery date2 | 0.997 | 1.000 | 0.998 | 40 | Multiple primary malignant tumors? | - | - | - |
| 19 | Site of pathologically Confirmed invasion | 1.000 | 1.000 | 1.000 | 41 | Deposits type | - | - | - |
| 20 | New primary cancer or MDS (myelodysplastic syndrome) | 0.833 | 1.000 | 0.909 | 42 | Residual adjacent adenoma? | - | - | - |
| 21 | Date of diagnosis for new primary cancer | 0.833 | 1.000 | 0.909 | 43 | Host lymphoid response | 0.946 | 0.889 | 0.917 |
| 22 | First progression (or recurrence) | 1.000 | 0.333 | 0.500 | Overall Average | 0.985 | 0.962 | 0.968 | |
2
Please note, the questions are re-evaluated with the new randomly selected patients in this study, and thus the results are slightly different from our previous work [13].